anti cd47 polyclonal antibody  (R&D Systems)

Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: PD-1/IL-2 bsAb protects CD8 + T cells from macrophage phagocytosis via STAT5-mediated upregulation of CD47 (A) Schematic of the Cleavage Under Targets and Tagmentation (CUT&Tag) assays workflow. (B) Distribution of STAT5 binding signals relative to transcription start sites (TSS) in CD8 + T cells treated with or without the PD-1/IL-2 bsAb. (C) Genomic annotation of differentially enriched STAT5 binding peaks in the bsAb-treated group. (D) KEGG pathway enrichment analysis of genes associated with STAT5 binding peaks. (E and F) Strategy and Venn diagram for identifying potential STAT5 downstream genes. (G) ChIP-qPCR analysis of STAT5 binding to the promoter regions of selected candidate genes ( n = 3). (H) Genome browser tracks showing STAT5 binding signals at the CD47 locus in control and PD-1/IL-2 bsAb-treated CD8 + T cells. (I) Schematic of the macrophage phagocytosis assay. (J) Representative confocal microscopy images showing macrophages (red) engulfing CD8 + T cells (green). Scale bars, 20 μm. (K) Flow cytometry quantification of the percentage of macrophages that had phagocytosed CD8 + T cells under the indicated conditions ( n = 3). Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance. Statistical significance was determined by unpaired Student’s t test or one-way ANOVA where appropriate.

Article Snippet: CD47 Polyclonal Ab , Proteintech , Cat#20305-1-AP; RRID: AB_10732838.

Techniques: Binding Assay, ChIP-qPCR, Control, Phagocytosis Assay, Confocal Microscopy, Flow Cytometry

Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: CD47 protects CD8 + T cells from macrophage clearance to boost antitumor immunity in SMARCA4-deficient NSCLC (A) Schematic of the adoptive T cell therapy experiment ( n = 8/group). (B) Representative in vivo bioluminescence images of mice from the indicated treatment groups at different time points. (C) Tumor growth curves, as measured by bioluminescence, for mice in each treatment group. (D) Individual tumor growth curves for mice in each treatment group. (E) Kaplan-Meier survival curves of mice from the four treatment groups. (F) Quantification by flow cytometry of donor-derived CD45.2 + CD8 + T cells among total tumor-infiltrating lymphocytes. (G) Representative flow cytometry plots for donor-derived CD45.2 + CD8 + T cells expressing the exhaustion markers PD-1, TIGIT, and TIM-3. (H) Quantification of the percentage of CD45.2 + CD8 + T cells expressing PD-1, TIGIT, and TIM-3. (I) The production of TNF-α by donor-derived CD45.2 + CD8 + T cells. (J) The production of IFN-γ by donor-derived CD45.2 + CD8 + T cells. (K) Representative immunofluorescence images of tumor sections. White: CD8, green: CD47, red: F4/80. Scale bars, 70 μm. (L) Schematic model depicting the proposed mechanism of action. Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance. Statistical significance was determined by one-way ANOVA.

Article Snippet: CD47 Polyclonal Ab , Proteintech , Cat#20305-1-AP; RRID: AB_10732838.

Techniques: In Vivo, Flow Cytometry, Derivative Assay, Expressing, Immunofluorescence

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

doi: 10.1007/s00432-024-05661-1

Figure Lengend Snippet: Representative example of CD47 expression in soft tissue sarcomas. A leiomyosarcoma 0; no staining of tumor cells, B undifferentiated pleiomorphic sarcoma 1 + ; less than 1/3 of the total tumor area positive (focal positivity), ( C ) dedifferentiated liposarcoma 2 + ; 1/3 – 2/3 of the total tumor area positive (moderate positivity) and D myxofibrosarcoma 3 + ; more than 2/3 of the total tumor area positive (diffuse positivity). Image magnification was 40 × and scale bars indicate 50 μm

Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

Techniques: Expressing, Staining

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

doi: 10.1007/s00432-024-05661-1

Figure Lengend Snippet: Expression of CD47 molecule among various histological subtypes of soft tissue sarcoma (STS). A CD47 scale positivity in ( n = 55) and B frequency of CD47 scale positivity among grade (G)1 + G2 and G3. C CD47 scale positivity and D frequency in liposarcoma (LPS), myxofibrosarcoma (MFS) and undifferentiated pleiomorphic sarcoma (UPS) ( n = 47). E CD47 scale positivity ( n = 22) and F its frequency among G1 + G2 and G3 in LPS. G CD47 scale positivity in LPS divided according to histological subtypes. H frequency of CD47 scale positivity in myxofibrosarcoma (MFS) ( n = 11) and I its frequency between G1 + G2 and G3. J CD47 scale positivity in high-grade undifferentiated pleiomorphic sarcoma (UPS) ( n = 16). CD47 scale positivity indicators: 0 no staining of tumor cells, 1 + expression in less than 1/3 of tumor tissue, 2 + expression in 1/3 to 2/3 of tumor tissue, and 3 + expression in more than 1/3 of tumor tissue. p values were calculated using Mann–Whitney U test

Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

Techniques: Expressing, Staining, MANN-WHITNEY

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

doi: 10.1007/s00432-024-05661-1

Figure Lengend Snippet: Chi-square test of independence to assess the association between CD47 expression and grade, metastases, and death

Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

Techniques: Expressing, Sampling

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

doi: 10.1007/s00432-024-05661-1

Figure Lengend Snippet: Chi-square test of independence to assess the association between CD47 expression (CD47 3 + vs CD47 0–2 +) and grade, metastases, and death

Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

Techniques: Expressing, Sampling

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

doi: 10.1007/s00432-024-05661-1

Figure Lengend Snippet: Association between CD47 expression and clinical outcome of patients with soft tissue sarcoma (STS). Kaplan–Meier curves depict the association between CD47 and A overall survival (OS), B metastasis-free survival, and C progression-free survival (PFS) in patients divided according to CD47 scale positivity. Kaplan–Meier curves show D OS, E metastasis-free survival, and PFS in CD47 0–2 + and CD47 3 + patients. Censored patients have not experienced the event of interest (progression, metastasis, death) by the end of the study period. The small vertical lines serve as a visual cue to underscore the presence of censored observations. p values were calculated by log-rank test

Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

Techniques: Expressing

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

doi: 10.1007/s00432-024-05661-1

Figure Lengend Snippet: Cox proportional hazards model assessing the prognostic significance of CD47 expression on overall survival (OS)

Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

Techniques: Expressing

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

doi: 10.1007/s00432-024-05661-1

Figure Lengend Snippet: Cox proportional hazards model assessing the prognostic significance of CD47 expression on progression-free survival (PFS)

Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

Techniques: Expressing

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Expression of CD47 in epithelial ovarian cancer tissues (100×) according to IHC staining. Specimens were stained with anti-CD47 polyclonal antibody. CD47 exhibits a predominantly membranous staining pattern, with no nuclear staining observed. A scale of 0–3 was employed: 0: ≤25% staining, 1: >25–50% positivity, 2: >50–75% positivity, cells showed membranous and/or cytoplasmic expression, 3: intense membranous and/or cytoplasmic expression of at least 75% of the tissue section. (A) CD47 IHC staining score of 0; (B) CD47 IHC staining score of 1; (C) CD47 IHC staining score of 2; (D) CD47 IHC staining score of 3. IHC, immunohistochemical.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Immunohistochemistry, Staining, Immunohistochemical staining

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Patient characteristics by pre-NACT CD47 expression

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques:

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Expression of CD47 in epithelial ovarian cancer tissues

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Immunohistochemistry

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Change of CD47 expression pre- and post-NACT. NACT, neoadjuvant chemotherapy.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Wilcoxon signed ranks test of the CD47 expression pre- and post-NACT

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Kaplan-Meier curves of CD47 expression for OS and PFS. The figure shows the Kaplan-Meier curves of OS and PFS for CD47 high and low expression in the cohort of 74 patients with EOC who received neoadjuvant chemotherapy, and four cases of stage I and II ovarian cancer were excluded from the analysis. EOC, epithelial ovarian cancer; OS, overall survival; PFS, progression-free survival; NACT, neoadjuvant chemotherapy.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Multivariate prognostic analysis

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: The expression of CD47 mRNA in ovarian epithelial cells (HOSE) and ovarian cancer cells (SKOV3 and ES2) according to RT-qPCR analysis of CD47 mRNA levels. The levels of CD47 mRNA expression in ES2 and SKOV3 cells were found to be significantly higher than those in HOSE cells (P<0.001). ***, P<0.001. RT-qPCR, reverse transcription quantitative polymerase chain reaction; mRNA, messenger RNA; HOSE, human ovarian surface epithelial cell.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Quantitative RT-PCR, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: The CD47 mRNA expression in SKOV3 and ES2 cells both with and without cisplatin treatment. A control group was treated with 0 µM of cisplatin, while a second group was treated with 4 µM of cisplatin for 48 hours to assess the expression of CD47 mRNA. (A) The expression of CD47 mRNA in SKOV3 treated with 0 and 4 µM cisplatin for 48 hours. Following 48 hours of treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was observed (P<0.001). (B) The expression of CD47 mRNA in ES2 treated with 0 and 4 µM of cisplatin for 48 hours. Following a 48-hour treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was evident (P<0.001). ***, P<0.001. mRNA, messenger RNA; DDP, cisplatin.

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Control

Journal: Gland Surgery

Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

doi: 10.21037/gs-24-400

Figure Lengend Snippet: Expression of cell surface CD47 protein in SKOV3 and ES2 cells following cisplatin treatment. (A) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in SKOV3 cells demonstrated a statistically significant increase (P<0.001). (B) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in ES2 cells demonstrated a notable increase (P<0.001).

Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 °C ( ).

Techniques: Expressing, Fluorescence

Journal: Frontiers in Cellular Neuroscience

Article Title: Neuroimmune pathways involvement in neurodegeneration of R6/2 mouse model of Huntington’s disease

doi: 10.3389/fncel.2024.1360066

Figure Lengend Snippet: CD47 expression in striatal neurons of R6/2 mice. Confocal laser scanning microscopy images of double-label immunofluorescence for CD47 (visualized in red fluorescence) and the Nissl-like fluorescent marker Neurotrace (visualized in green fluorescence). (A–D) Images show the expression pattern of CD47 in the striatum of 5 and 13 weeks-old wild-type mice and in 5 and 13 weeks-old R6/2 mice. (E,F) Detail of cytoplasmic membrane CD47 expression in 13 weeks-old Wt mice. In 13 weeks-old R6/2 mice CD47 is lower due to cell death process (G) Histogram shows CD47 intensity quantification which is significantly decreased in the striatal neurons of 13 weeks-old R6/2 mice [Genotype effect F (1,153) = 11.97, *** P = 0.0007]. (H,I) Tukey’s multiple comparisons analysis revealed a significant protein decrease of striatal neuronal CD47, as evaluated by western blotting in R6/2 mice [Genotype effect F (1,20) = 8.667, ** P = 0.0080; Time effect F (1,20) = 5.802, ** P = 0.0258; Genotype X Time Interaction F (1,20) = 37.89, *** P < 0,0001].

Article Snippet: Coronal brain sections were incubated with the marker CD47 (BS-21460R, rabbit polyclonal anti-CD47, Bioss, USA) at 1:200 dilution in a 0.1 M PB solution containing 0.3% Triton X-100 for 72 h at 4°C.

Techniques: Expressing, Confocal Laser Scanning Microscopy, Immunofluorescence, Fluorescence, Marker, Membrane, Western Blot